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Abstract Treatment with sodium tanshinone IIA sulfonate
(STS) may ameliorate blood-brain barrier (BBB) damage in
acute ischemic stroke patients receiving recombinant tissue
plasminogen activator (rt-PA) thrombolysis and improve
stroke patients’ outcome. This randomized, single-center,
placebo-controlled clinical trial investigated the potential ef-
fects and underlying mechanisms of STS. Forty-two acute
ischemic stroke patients receiving intravenous rt-PA throm-
bolysis were randomized to intravenous administration either
with STS (60 mg/day) (n = 21) or with equivalent volume of
saline as a placebo (n = 21) after randomization for 10 days.
Clinical outcomes, computer tomography perfusion (CTP)
imaging with permeability-surface area product (PS) maps
and serum levels of BBB damage biomarkers, were compared
between the two groups. The percentage of patients with ex-
cellent functional outcome indicated by a 90-day mRS ≤1 was
significantly higher in the STS group than in the placebo
group (p = 0.028). For patients with CTP imaging (n = 30),
PS in the ipsilateral lesion (p = 0.034) and relative PS
(p = 0.013) were significantly lower in the STS group than
that in placebo. STS-treated patients also had lower levels of
matrix metalloproteinase (MMP)-9 (p = 0.036) and claudin-5
(p = 0.026), but higher levels of tissue inhibitor of metallopro-
teinase (TIMP)-1 (p = 0.040) than those in the placebo group.
Post-stroke STS treatment could improve neurologic function-
al outcomes for acute ischemic stroke patients following rt-PA
treatment by reducing BBB leakage and damage, which might
be mechanistically associated with MMP-9 inhibition.
Keywords Blood-brain barrier . Sodium tanshinone IIA
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Introduction
Blood-brain barrier (BBB) breakdown is a major contributing
factor to ischemic brain injury or hemorrhagic transformation
(HT) and often leads to poor outcomes in acute ischemic stroke
patients receiving recombinant tissue plasminogen activator (rt-
PA) treatment [1, 2]. Tight-junction proteins such as claudin,
junctional adhesion molecule, and occludin play essential roles
in maintaining BBB integrity. Measurements of permeability-
surface area product (PS), an indicator of BBB permeability, by
computer tomography perfusion (CTP) imaging have been suc-
cessfully applied for early identification of BBB damage and HT
development in acute stroke patients [3, 4].
Sodium tanshinone IIA sulfonate (STS) is a water-soluble
derivative of tanshinone IIA, a main bioactive component
isolated from the roots of the Chinese herb Salviae
miltiorrhiza Bunge (Danshen) [5]. STS has been widely used
for treatments of cardiovascular and cerebrovascular diseases
in China [6, 7]. In mice with cerebral ischemia, STS could
protect BBB and had a patent in China [8, 9]. Here, we
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hypothesized that STS could work as a BBB protective agent
that help acute ischemic stroke patients who received throm-
bolysis treatment recover better. In this study, we used CTP-
derived PS to reveal whether treatment with STS could reduce
BBB leakage in acute ischemic stroke patients receiving rt-PA




This single-centered, randomized, double-blinded pro-
spective study was approved by the ethics committee of
Drum Tower Hospital, Medical School of Nanjing
University. An entry was made in the Chinese clinical
trial registry (ChiCTR-ONRC-14004659). The inclusion
criteria were as follows: (1) acute ischemic stroke patients
receiving rt-PA treatment, (2) at age between 18 to
80 years old, and (3) willing to participate in all follow-
up neurologic and imaging examinations. We excluded
patients with presence of platelet abnormali t ies
(PLT < 100 or >300 × 109/L), severe bleeding disorders,
contraindications to iodinated contrast agent, a history of
severe renal failure, or known or suspected infection.
Informed consents were obtained from all participants in-
volved in this study. Randomization sequences were com-
puter generated. The flow chart of patient cohort selection
is shown in Fig. 1.
Treatments
After rt-PA thrombolysis, STS (60 mg per day) was intrave-
nously administrated daily to patients in the STS group for
10 days, while patients in the placebo group received equiva-
lent administrations of saline. All participants received aspirin
after thrombolysis 24 h for acute ischemic stroke.
Neurologic Assessment
Neurologic function outcomes were assessed using the
National Institutes of Health Stroke Scale (NIHSS) score at
0, 24 h, and 10 days; activities of daily living (ADLs) score at
0 h and 10 days; and the modified Rankin Scale (mRS) at
90 days.
CTP Scan Protocol and Image Analysis
CT perfusion and non-contrast CT scans were performed on a
64-slice CT scanner (Discovery CT750 HD, GE Healthcare,
Milwaukee, WI, USA). CTP started with intravenous injec-
tion of 50 mL of iodinated contrast agent (350 mg/mL,
Omnipaque, GE Healthcare, Shanghai, China) followed by a
saline flush of 45 mL at 5 mL/s. CTP scans began after a delay
of 5 s from contrast injection, and the following technical
settings were applied: 80 kVp, 150 mAs, temporal sampling
rate of 2 s for 60 s, and total axial coverage of 40 mm at 5-mm
slice thickness.
All CTP images were analyzed by experienced radiol-
ogists who were blinded to this research. For the PS maps
and data, manually drawn region of interests (ROIs) in the
ipsilateral hemisphere were compared to those in the con-
tralateral hemisphere. PS values were calculated using
CTP software (CT Kinetics, GE Healthcare, China). The
corresponding ROIs for the contralateral side were gener-
ated automatically by mirroring the ipsilateral ROIs, and
the relative PS (rPS) was defined as ipsilateral/
contralateral ROIs.
Measurement of BBB Damage Biomarkers
Venous blood were collected at 0, 24 h, and 10 days, and the
separated serum was stored in aliquots at −80 °C until bio-
chemical analysis.
Serum levels of matrix metalloproteinase (MMP)-2
(R&D, Minneapol i s , IL , USA), MMP-9 (R&D,
Minneapolis, IL, USA), tissue inhibitor of metalloprotein-
ase (TIMP)-1 (R&D, Minneapolis, IL, USA), claudin-5
(CusaBio, Wu han, China), and zonula occluden (ZO)-1
(CusaBio, Wu han, China) were measured using commer-
cially available ELISA kits according to the manufac-
turer’s instructions.
Study Outcomes
The outcomes were the integrity of blood-brain barrier by
measurement of PS, MMP-9, MMP-2, TIMP-1, claudin-5,
and ZO-1 and neurologic improvement by the score on
NIHSS and the mRS at 90 days. Safety outcome measures
the incidence of adverse event.
Statistical Analysis
All results were analyzed using SPSS (SPSS version
22.0, Chicago, Illinois, USA). The data were shown as
mean ± standard deviation (SD) or medians with inter-
quartile ranges for continuous variables and proportions
for categorical variables. Continuous variables were
compared using t tests, and categorical variables were
analyzed using the Pearson χ2 test or Fisher’s exact





From February 2014 to February 2016, 46 patients receiving
rt-PAwere included: 23 patients were treated with STS and 23
with placebo as control. Three patients had uncompleted treat-
ment due to transferring to another department, and one
patient was lost follow-up, thus leaving 21 patients in each
group for clinical and prognostic analysis. General clinical
characteristics (e.g., age, sex, risk factors, and NIHSS scores)
and the distribution of baseline NIHSS at admission were
similar (Table 1 and Fig. 2). In the 42 patients, 12 were un-
available to attend the second CT examinations, leaving 16
and 14 patients for imaging analysis in the STS and placebo
groups, respectively.
Fig. 1 Flow chart showing patient cohort selection in this study
Table 1 Patients characteristics
STS (N = 21) Placebo (N = 21) F/χ2 P value
Average age (years) 63.81 ± 9.872 63.62 ± 11.561 1.321 0.954
Male (%) 14 (66.7%) 14 (66.7%) 0.000 1.000
Hypertension 12 (57.1%) 17 (81.0%) 2.785 0.181
Diabetes 3 (14.3%) 5 (23.8%) 0.618 0.694
Hyperlipidemia 7(33.3%) 6 (28.6%) 0.111 1.000
Hyperhomocysteinemia 5 (23.8%) 4 (19.0%) 0.141 1.000
Atrial fibrillation 4 (19.0%) 2 (9.5%) 0.778 0.663
Coronary heart disease 3 (14.3%) 1 (4.8%) 1.105 0.606
Previous cerebral infarction 2 (9.5%) 3 (14.3%) 0.227 1.000
Smoking 5 (23.8%) 3 (14.3%) 0.618 0.238
Alcohol use 6 (28.6%) 2 (9.5%) 2.471 0.238
At admission
SBP (mmHg) 153.48 ± 17.665 154.81 ± 21.558 1.896 0.828
DBP (mmHg) 86.62 ± 14.333 85.29 ± 13.050 0.527 0.754
Glu (mmol/L) 7.93 ± 2.595 8.66 ± 4.070 6.424 0.492
Time to rt-PA (min) 214.62 ± 43.246 198.71 ± 42.717 0.021 0.238
NIHSS 8.05 ± 4.522 7.38 ± 5.220 0.427 0.661
ADL 54.29 ± 25.801 53.33 ± 27.034 0.054 0.908
SBP systolic blood pressure, DBP diastolic blood pressure
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Clinical Outcomes
A battery of neurologic function assessments was used to
investigate whether patients with acute ischemic stroke could
benefit from STS after rt-PA thrombolysis. Results showed
that in whole 42 patients (21 STS and 21 placebo), there were
more patients with a 90-day mRS score ≤1 (an excellent func-
tional outcome) in the STS group than that in the placebo
group. Though there is no statistical significance, STS did
decrease the incidence of HT during hospitalization. No sig-
nificant difference was found in the means of NIHSS and
ADL score at 10 days after rt-PA treatment between the two
groups (Table 2 and Fig. 3).
Neuroimaging of BBB Permeability between STS
and Placebo Groups
CTP was performed to reveal the effects of STS treatment
on BBB integrity. Twenty-four hours after rt-PA treat-
ment, a baseline CTP was performed for each patient
and there was no significant difference in BBB permeabil-
ity (ipsilateral or contralateral and rPS) between the two
groups. The follow-up CTP was performed at 10 days
after the treatments. Moreover, the STS group showed
significantly lower levels of ipsilateral PS and rPS than
did the placebo group at 10 days (Table 3 and Fig. 4).
Serum BBB Damage Biomarkers
Serum levels of MMP-9, MMP-2, TIMP-1 and tight-junction
proteins, including claudin-5 and ZO-1, in 30 patients (16 STS
and 14 placebo) were measured to demonstrate BBB damage.
The STS group had lower MMP-9 (633.352 vs 750.739 ng/ml,
p = 0.036, Fig. 5a) and claudin-5 (337.822 vs 407.763 pg/ml,
p = 0.026, Fig. 5b) levels but higher TIMP-1 expression
(520.652 vs 459.567 ng/ml, p = 0.040, Fig. 5c) than did the
placebo group at 10 days after thrombolytic therapy. However,
at acute phase (0 and 24 h), there were no significant differences
in all biomarkers between the two groups.
Discussion
Current rt-PA thrombolytic therapy could augment BBB dis-
ruption in the acute stroke patients, which increase ischemic
brain injury or HT [10]. Therefore, therapeutic strategies de-
signed to alleviate BBB damage are needed to improve clin-
ical outcomes of rt-PA thrombolysis [11]. Prognosis of rt-PA-
treated patients with mRS ≤1 (an excellent functional out-
come) was reported differently, from 42.7% to 54.6% at
3 months [12–14]. As Tsivgoulis reported, mRS ≤1 scores
was 42.7%, which is similar to our control group (mRS ≤ 1
scores was 42.86%). Effect of rt-PA therapy is affected by
Fig. 2 The distribution of
baseline NIHSS between the two
groups
Table 2 Patient clinical
outcomes All enrolled patients STS (N = 21) Placebo (N = 21) F/χ
2 P value
10 day-NIHSS 2.81 ± 2.64 4.10 ± 3.81 1.853 0.211
10 day-ADL 82.62 ± 20.89 72.38 ± 25.18 1.016 0.159
90 day-mRS ≤ 1 16 (76.19%) 9 (42.86%) 6.462 0.028*
HT during hospitalization 2 (9.52%) 5 (23.81%) 1.543 0.410
*p<0.05
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many factors, such as treatment time since stroke onset, age,
stroke severity, BBB integrity, and so on. Our study found that
there were more patients with a 90-day mRS score ≤1 in the
STS group compared with the placebo group.
To investigate whether the neuroprotection of STS is
associated with decreasing BBB disruption, PS was de-
tected by dynamic contrast-enhanced CT [10, 15, 16].
Recently, CTP-derived PS quantification has been used
to predict BBB permeability and HT for acute stroke pa-
tients because of its good reproducibility in hemodynamic
measurement, wide accessibility, and relatively low cost
[2, 4, 10]. The neuroimaging results from this study
showed that STS treatment could reduce BBB-PS to ame-
liorate BBB damage and benefit clinical outcomes post-rt-
PA thrombolysis in acute stroke patients. Pathologically,
release of tight junction adhesion molecules to blood cir-
culation is associated with compromised BBB integrity in
ischemic stroke [3]. Tanshinone IIA (precursor of STS)
treatment has been previously shown to diminish BBB
breakdown in experimental model of ischemic stroke [8,
9] and autoimmune encephalomyelitis [17]. Similarly, in
this study, we found that STS treatment decreased the
levels of BBB damage biomarkers, MMP-9 and claudin-
5, in acute ischemic stroke patients after intravenous
thrombolysis. From our observations, STS seemed to re-
duce the effects of BBB disruption by inhibiting MMP-9
activity and increasing expression of TIMP-1.
Next, we evaluated the infarct volumes and found no dif-
ference between the STS group (2.020 ± 1.762 cm3) and the
placebo group (2.415 ± 3.083 cm3) after 10 days of treatment
(p = 0.676). It suggested that STS did not reduce BBB damage
through decreasing infarct volumes.
Furthermore, to study whether STS decreases cerebral
hemorrhagic transformation, STS did reduce the trend of ce-
rebral hemorrhagic transformation, but it was not significant,
which may be correlated to the small sample research. STS
could inhibit peripheral inflammatory cells into brain after
stroke by suppressing BBB injury, which protects brain from
immuno-inflammation and improves recover of stroke
patients.
How STS protects the BBB from injury after stroke re-
mains unclear. STS might improve BBB damage by
Fig. 3 Distribution of mRS in the
STS and placebo groups at
3 months after treatment. STS had
more patients with 90-day mRS
score ≤1 in the whole 42 patients
Table 3 BBB permeability
measured by CTP-derived PS Parameters STS (N = 16) Placebo (N = 14) P value
Baseline
Ipsilateral PS value (ml/100 g/min) 0.373 ± 0.062 0.395 ± 0.073 0.371
Contralateral PS value (ml/100 g/min) 0.175 ± 0.025 0.179 ± 0.022 0.703
rPS 2.128 ± 0.219 2.225 ± 0.380 0.394
PS region area (cm2) 2.586 ± 2.461 2.893 ± 3.131 0.766
10 days after STS or placebo
Ipsilateral PS value (ml/100 g/min) 0.266 ± 0.083 0.332 ± 0.079 0.034*
Contralateral PS value (ml/100 g/min) 0.170 ± 0.170 0.172 ± 0.017 0.761
rPS 1.548 ± 0.393 1.910 ± 0.345 0.013*
PS region area (cm2) 1.773 ± 1.563 2.287 ± 2.214 0.464
Infarct volumes (cm3) 2.020 ± 1.762 2.415 ± 3.083 0.676
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suppressing astrocyte-mediated inflammation or decreasing
brain microvascular endothelial cell apoptosis after stroke.
Together, the neuroimaging and pathological evidence of
our study could delineate the mechanistic pathway of STS
treatment in improving BBB dysfunction post-rt-PA
thrombolysis.
However, we had several limitations in the current work.
First, to better elucidate the relation between BBB damage
biomarkers and PS, MMPs and tight junction proteins obtain-
ed from cerebrospinal fluid (CSF) examination by lumbar
puncture and a correlation study are needed in the future.
Second, lack of BBB-PS measurements from CTP imaging
at 90 days could not fully evaluate the effects of STS treatment
on BBB repair. In addition, our study had a small sample size
although the randomization has been applied. These questions
will be addressed in our future work.
Fig. 4 BBB-PS maps from the
STS and placebo groups.
Quantitative PS maps of both
groups at baseline (a, c) and
10 days after STS or placebo
treatment (b, d). At day 10, the
patient with STS treatment
showed a significant decline in
BBB-PS when compared to the
placebo
Fig. 5 Serum levels of BBB
damage biomarkers. Serum
MMP-9 (a), claudin-5 (b), and
TIMP-1 (c) protein levels were
measured at different time points
using ELISA in the STS (n = 16)
and placebo groups (n = 14). STS
showed a lower MMP-9 and
claudin-5 and higher TIMP-1
expression after 10 days treatment
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In conclusion, both neuroimaging and serum biomarkers of
BBB damage in this study demonstrated that acute ischemic
stroke patients might benefit from STS treatment by
ameliorating/diminishing BBB disruption following rt-PA
thrombolysis.
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